Email this article 
Hide
Show all
Original Research
Consequences of rpoB mutations missed by the GenoType MTBDRplus assay in a programmatic setting in South Africa
Submitted: 06 June 2022 | Published: 06 February 2023
About the author(s)
Nomonde R. Mvelase, Department of Medical Microbiology, KwaZulu-Natal Academic Complex, National Health Laboratory Service, Durban, South Africa; and, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South AfricaLindiwe P. Cele, Department of Public Health, Epidemiology and Biostatistics Unit, Sefako Makgatho Health Sciences University, Pretoria, South Africa
Ravesh Singh, Department of Medical Microbiology, KwaZulu-Natal Academic Complex, National Health Laboratory Service, Durban, South Africa; and, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa
Yeshnee Naidoo, KwaZulu-Natal Research Innovation and Sequencing Platform, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa; and, Centre for Epidemic Response and Innovation, School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa
Jennifer Giandhari, KwaZulu-Natal Research Innovation and Sequencing Platform, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
Eduan Wilkinson, KwaZulu-Natal Research Innovation and Sequencing Platform, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa; and, Centre for Epidemic Response and Innovation, School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa
Tulio de Oliveira, KwaZulu-Natal Research Innovation and Sequencing Platform, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa; and, Centre for Epidemic Response and Innovation, School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa; and, Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa
Khine Swe Swe-Han, Department of Medical Microbiology, KwaZulu-Natal Academic Complex, National Health Laboratory Service, Durban, South Africa; and, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa
Koleka P. Mlisana, Department of Medical Microbiology, KwaZulu-Natal Academic Complex, National Health Laboratory Service, Durban, South Africa School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa; and, Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, South Africa
Abstract
Background: Rifampicin resistance missed by commercial rapid molecular assays but detected by phenotypic assays may lead to discordant susceptibility results and affect patient management.
Objective: This study was conducted to evaluate the causes of rifampicin resistance missed by the GenoType MTBDRplus and its impact on the programmatic management of tuberculosis in KwaZulu-Natal, South Africa.
Methods: We analysed routine tuberculosis programme data from January 2014 to December 2014 on isolates showing rifampicin susceptibility on the GenoType MTBDRplus assay but resistance on the phenotypic agar proportion method. Whole-genome sequencing was performed on a subset of these isolates.
Results: Out of 505 patients with isoniazid mono-resistant tuberculosis on the MTBDRplus, 145 (28.7%) isolates showed both isoniazid and rifampicin resistance on the phenotypic assay. The mean time from MTBDRplus results to initiation of drug-resistant tuberculosis therapy was 93.7 days. 65.7% of the patients had received previous tuberculosis treatment. The most common mutations detected in the 36 sequenced isolates were I491F (16; 44.4%) and L452P (12; 33.3%). Among the 36 isolates, resistance to other anti-tuberculosis drugs was 69.4% for pyrazinamide, 83.3% for ethambutol, 69.4% for streptomycin, and 50% for ethionamide.
Conclusion: Missed rifampicin resistance was mostly due to the I491F mutation located outside the MTBDRplus detection area and the L452P mutation, which was not included in the initial version 2 of the MTBDRplus. This led to substantial delays in the initiation of appropriate therapy. The previous tuberculosis treatment history and the high level of resistance to other anti-tuberculosis drugs suggest an accumulation of resistance.
Keywords
Metrics
Total abstract views: 4895Total article views: 4421
Crossref Citations
1. Pretreatment attrition after rifampicin-resistant tuberculosis diagnosis with Xpert MTB/RIF or ultra in high TB burden countries: a systematic review and meta-analysis
Christelle Geneviève Jouego, Tom Decroo, Palmer Masumbe Netongo, Tinne Gils
BMJ Global Health vol: 10 issue: 1 first page: e015977 year: 2025
doi: 10.1136/bmjgh-2024-015977
2. Emergence of bedaquiline-resistant tuberculosis and of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains with rpoB Ile491Phe mutation not detected by Xpert MTB/RIF in Mozambique: a retrospective observational study
Ivan Barilar, Tatiana Fernando, Christian Utpatel, Cláudio Abujate, Carla Maria Madeira, Benedita José, Claudia Mutaquiha, Katharina Kranzer, Tanja Niemann, Nalia Ismael, Leonardo de Araujo, Thierry Wirth, Stefan Niemann, Sofia Viegas
The Lancet Infectious Diseases vol: 24 issue: 3 first page: 297 year: 2024
doi: 10.1016/S1473-3099(23)00498-X
3. Analysis of rpoB mutations associated with rifampicin resistance in Mycobacterium tuberculosis isolates in Malawi
Stewart Soko, Pizga Kumwenda
BMC Infectious Diseases vol: 26 issue: 1 year: 2026
doi: 10.1186/s12879-026-13126-8
4. Discordance between genotypic and phenotypic methods for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis and the correlation with patient treatment outcomes
Zegeye Bonsa, Mulualem Tadesse, Getu Balay, Wakjira Kebede, Gemeda Abebe
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases vol: 34 first page: 100410 year: 2024
doi: 10.1016/j.jctube.2023.100410
5. Undetected rifampicin-resistant tuberculosis associated with rpoB I491F and V170F mutations in Botswana: Diagnostic implications
Tuelo Mogashoa, Justice T. Ngom, Johannes Loubser, Kedumetse Seru, Tuduetso Molefi, One Stephen, Rosemary M. Musonda, Simani Gaseitsiwe, Robin M. Warren, Anzaan Dippenaar, Elizabeth M. Streicher, Sikhulile Moyo
Journal of Global Antimicrobial Resistance vol: 46 first page: 171 year: 2026
doi: 10.1016/j.jgar.2025.12.005
6. Whole genomic analysis uncovers high genetic diversity of rifampicin-resistant Mycobacterium tuberculosis strains in Botswana
Tuelo Mogashoa, Johannes Loubser, Ontlametse T. Choga, Justice Tresor Ngom, Wonderful T. Choga, Mpaphi B. Mbulawa, Tuduetso Molefi, One Stephen, Topo Makhondo, Kedumetse Seru, Patience Motshosi, Boitumelo Zuze, Joseph Makhema, Rosemary M. Musonda, Dimpho Otukile, Chawangwa Modongo, Botshelo T. Kgwaadira, Keabetswe Fane, Simani Gaseitsiwe, Rob M. Warren, Sikhulile Moyo, Anzaan Dippenaar, Elizabeth M. Streicher
Frontiers in Microbiology vol: 16 year: 2025
doi: 10.3389/fmicb.2025.1535160
7. Therapeutic drug monitoring–guided treatment of XDR TB with an RpoB I491F mutation—a case report
Angela Klingmüller, Sylvia Zuber, Ada M Hoffmann, Niklas Köhler, Isabelle Suárez, Tim Preßel, Stefan Niemann, Viola Dreyer, Laurent A Decosterd, Eva Choong, Beatrice Schütz, Inna Friesen, Jan Rybniker
JAC-Antimicrobial Resistance vol: 8 issue: 1 year: 2026
doi: 10.1093/jacamr/dlaf251
8. Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India
Raj Narayan Yadav, Manpreet Bhalla, Shubhada Shenai, Surendra Kumar Sharma, Ritu Singhal
Indian Journal of Medical Microbiology vol: 57 first page: 100925 year: 2025
doi: 10.1016/j.ijmmb.2025.100925
9. Clinical, Radiological, and Molecular Profiles of Rifampicin-resistant Pulmonary Tuberculosis: A Cross-sectional Study from a Tertiary Referral Center in Indonesia
David Christianto, Ni Made Mertaniasih, Ariani Permatasari, Priyo Budi Purwono, Pepy Dwi Endraswari, Atika
Journal of Pure and Applied Microbiology vol: 19 issue: 4 first page: 3095 year: 2025
doi: 10.22207/JPAM.19.4.51
10. Direct detection of drug-resistant Mycobacterium tuberculosis using targeted next generation sequencing
Shannon G. Murphy, Carol Smith, Pascal Lapierre, Joseph Shea, Kruthikaben Patel, Tanya A. Halse, Michelle Dickinson, Vincent Escuyer, Marie Claire Rowlinson, Kimberlee A. Musser
Frontiers in Public Health vol: 11 year: 2023
doi: 10.3389/fpubh.2023.1206056
11. The Relative Positioning of Genotyping and Phenotyping for Tuberculosis Resistance Screening in Two EU National Reference Laboratories in 2023
Richard Anthony, Ramona Groenheit, Mikael Mansjö, Rina de Zwaan, Jim Werngren
Microorganisms vol: 11 issue: 7 first page: 1809 year: 2023
doi: 10.3390/microorganisms11071809
12. Decoding antibiotic resistance in tuberculosis: Role of RRDR and non-RRDR mutations in diagnostic perspectives
Risha Hazarika, Sanjukta Patra
Biochemical and Biophysical Research Communications vol: 812 first page: 153563 year: 2026
doi: 10.1016/j.bbrc.2026.153563
13. Detection of I491F and V170F rpoB mutations associated with misdiagnosis of rifampicin resistance among patients with drug-susceptible tuberculosis treatment failure, Myanmar, 2022
Phyu Win Ei, Mi Mi Htwe, Myat Htut Nyunt, Aye Su Mon, Zaw Myint, Wint Wint Nyunt, Su Mon Win, Sandar Aung, Wai Myat Thwe, Wah Wah Aung
Journal of Global Antimicrobial Resistance vol: 41 first page: 169 year: 2025
doi: 10.1016/j.jgar.2024.12.026